Vaccines for children FY25
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75D30125D00198
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
CDC Pittsburgh
Centers for Disease Control and Prevention, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- FY25 Vaccines for Children Solicitation · 75D30125R00065 · Posted Jan 16, 2025
- Last date to order 100% complete
- IDV ceiling
- $928,389,595.14
- Maximum order
- $793,016,569.64
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The Centers for Disease Control and Prevention Pittsburgh awarded an indefinite-delivery contract to Glaxosmithkline, LLC for pediatric vaccines under the Vaccines for Children (VFC) program with a ceiling of $928,389,595.14 on April 1, 2025. This is a multiple-award contract with no set-aside.
Work is performed at Glaxosmithkline manufacturing facilities in Chamblee, Georgia, with delivery of vaccines required to CDC distribution centers in Olive Branch, Mississippi, Aurora, Colorado, and Clermont, Kentucky. The contract procures standard commercial pediatric vaccines to support immunization for Medicaid-eligible, uninsured, American Indian/Alaska Native, and underinsured children. Contractors must hold FDA licensure as vaccine manufacturers under 42 U.S.C. 1396s, provide vaccines with a minimum 12-month shelf life, maintain electronic data interchange capabilities, and interface with the CDC's Vaccine Tracking System. Delivery is required within 15 working days to CDC distribution centers.
The period of performance runs from April 1, 2025, through March 31, 2026. Evaluation criteria include technical capability, pricing, and past performance. Federal Excise Tax is required in pricing and varies from $0.75 to $4.50 per dose depending on vaccine type. The solicitation posted January 16, 2025, with a proposal due date of January 30, 2025. Potential maximum order quantities range from 100 doses to 13 million doses across different vaccine types.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$1,221 | |
| Funding Only Action | $78,198,528 | |
| Funding Only Action | $156,936,667 | |
| Funding Only Action | $222,828,436 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $171,998,575 | |
| Funding Only Action | $163,055,584 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75D30125D00198?
75D30125D00198 was awarded to Glaxosmithkline, LLC by CDC Pittsburgh (Centers for Disease Control and Prevention) on April 1, 2025.
How much is contract 75D30125D00198 worth?
75D30125D00198's own ceiling is $928,389,595. A single order can be worth up to $793,016,570.
Who can order from contract 75D30125D00198?
75D30125D00198 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75D30125D00198 competed?
The extent of competition for 75D30125D00198 was full and open competition. The government received 5 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV